ACERCA DE ESTE PODCAST 🔗

Duración media del audio:
7 minutes
Inglés
Estados Unidos
31 episodios
desde 13 de febrero de 2015
episodic

ÚLTIMO EPISODIO 🔗

Prof Gribben (Queen Mary University London, London, UK) and Prof Stilgenbauer (Universitätsklinikum Ulm, Ulm, Germany) review the data and opinions arising from ASH 2014 about the treatment of chronic lymphocytic leukaemia (CLL) for ecancertv. The experts offer a comprehensive analysis of the curr…

BUSCAR EPISODIOS ANTERIORES

Buscar episodios anteriores de ASH 2014.

EPISODIOS ANTERIORES

Prof Keith Stewart of the Mayo Clinic, Scottsdale, USA talks to ecancertv at ASH 2014 about the phase III ASPIRE study looking at the use of carfilzomib in multiple myeloma. “By adding carfilzomib to the gold standard in multiple myeloma therapy, we are observing an unprecedented duration of remis…
Dr Stephan Grupp - The Children's Hospital of Philadelphia, Philadelphia, USA talks to ecancertv at ASH 2014 about the use of T cell therapy for children with aggressive leukaemia.
Prof Marivi Mateos of the University Hospital of Salamanca, Salamanca, Spain speaks to ecancertv at ASH 2014 about the results of a phase I study on the use of daratumumab, an anti-CD38 antibody, in combination with standard approaches to treat relapsed multiple myeloma.
Prof Burnett (Head of Haematology Department of Medical Genetics, Cardiff, Wales) and Prof Amadori (Tor Vergata University Hospital, Rome, Italy) review the data and opinions arising from ASH 2014 about the treatment of acute myeloid leukaemia (AML) for ecancertv. They debate the use of intensifie…
Dr Craig Moskowitz of the Memorial Sloan Kettering Cancer Center, New York, USA talks to ecancertv at ASH 2014 about the findings of a phase III trial which compared brentuximab vedotin (BV), an antibody targeting the CD30 protein on Hodgkin lymphoma cells, with placebo in 327 patients at risk of p…
Dr Thomas Martin, MD, of the University of California, San Francisco, USA talks to ecancertv at ASH 2014 about his work looking at the use of SAR, an anti-CD38 antibody, in the treatment of aggressive multiple myeloma.
Dr Joe Alvarnas of the City of Hope National Medical Center, Los Angeles, USA talks to ecancertv at ASH 2014 about his work looking at stem cell transplants in HIV-associated lymphoma. "They're rather extraordinary results," he says.
Prof Amrita Krishnan of the City of Hope National Medical Center, Los Angeles, USA "Ultimately, if you really want to 'win the game,' you have to cure the HIV and cure the lymphoma," Prof Krishnan tells ecancertv at ASH 2014, describing her work on modifying haematopoietic progenitor cells with gen…
Dr Catherine Bollard of the George Washington University, Washington, USA discusses key abstracts showcased at ASH 2014 with ecancertv. Here, she talks about Dr Stephan Grupp's work with T cell therapy for children with aggressive leukaemia, and his remarkable results. What's the next step for clin…
Descargo de responsabilidad: El podcast y el arte incluidos en esta página son de ecancertv, que es propiedad de su propietario y no está afiliado ni respaldado por Listen Notes, Inc.